Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805955 | 0.86 | SCN9A (0.78) | SCN9ADPP4 | |
| SCHEMBL15578145 | 0.78 | LGMN (0.53) | SCN9AKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL6503652 | 0.78 | CCR8 (0.59) | KDM4EALDH1A1TSHRHSD17B10MAPT | |
| SCHEMBL805966 | 0.77 | SCN9A (0.69) | SCN9AKDM4EALDH1A1GAAKMT2A | |
| SCHEMBL805965 | 0.76 | SCN9A (0.70) | SCN9A | |
| SCHEMBL787594 | 0.76 | SCN9A (1.00) | SCN9A | |
| SCHEMBL787301 | 0.76 | SCN9A (1.00) | SCN9A | |
| SCHEMBL29421431 | 0.76 | SCN9A (1.00) | SCN9A | |
| SCHEMBL1749330 | 0.74 | MAPT (0.68) | KDM4EALDH1A1TSHRMAPTHPGD | |
| SCHEMBL21236848 | 0.74 | SCN9A (0.71) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616441-B1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9611222-B2 | Pyridine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-09-17 | — | — | US | disclosed |
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-09-17 | — | — | US | disclosed |
| US-9056832-B2 | Pyridine compounds and the users thereof | PURDUE PHARMA L.P. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056832-B2 | Pyridine compounds and the users thereof | PURDUE PHARMA L.P. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012035421-A2 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, CACNA1A, KCNA1 | SCN9A 148/4885KDM4E 1781/4885ALDH1A1 172/4885 |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | TRPV1, CACNA1A, KCNA1 | SCN9A 148/4885KDM4E 1781/4885ALDH1A1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.